This could underestimate the perceived benefit of adding chemotherapy, and as such, for patients with stage II/III resected NSCLC with EGFR mutation, we strongly suggest adjuvant chemotherapy be given in addition to osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.